Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

Head and Neck Carcinoma Clinical Trial

Official title:

A Randomized Study of Head and Neck Radiotherapy With or Without Customized 3D Printed Oral Stents

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04870762
• Other study ID #: 2020-1153
• Secondary ID: NCI-2021-0322120
• Status: Recruiting
• Phase: Phase 2
• Start date: May 26, 2021
• Est. completion date: November 6, 2024

Study information

• Verified date: March 2024
• Source: M.D. Anderson Cancer Center
• Contact: Eugene Koay, MD
• Phone: (713) 792-9149
• Email: ekoay[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients' teeth and gums during radiation therapy. A customized, 3D-printed oral stent may help to reduce mouth blisters and/or sores that may develop in patients while receiving head and neck radiation therapy.

Description:

PRIMARY OBJECTIVE: I. To evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent. SECONDARY OBJECTIVES: I. To record patient reported outcomes during radiotherapy. II. To evaluate patient narcotic use during radiotherapy. III. To evaluate the imaging and dosimetric differences in head and neck radiotherapy with and without a customized 3D printed oral stent. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients wear 3D printed oral stent during standard of care radiotherapy. ARM II: Patients receive standard of care during treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 93
• Est. completion date: November 6, 2024
• Est. primary completion date: November 6, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is dispositioned to receive definitive or adjuvant radiotherapy for treatment of a diagnosed head and neck malignancy that includes
• Well lateralized tonsil cancer with no soft palate involvement and qualifies for ipsilateral radiotherapy
• Well lateralized buccal cancer that qualifies for ipsilateral radiotherapy
• Well lateralized parotid cancer that qualifies for ipsilateral radiotherapy
• A cancer that involves the nasal cavity and does not require coverage of the oral cavity or oropharynx
• A cancer that involves the maxillary sinus and does not require coverage of the oral cavity or oropharynx
• A cancer that involves the base of tongue
• Age 18 or older
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
• The patient will receive radiotherapy with either cisplatin, carboplatin, or cetuximab
• Signed study-specific consent form

Exclusion Criteria:

• Prior head and neck radiotherapy
• Patient is unable to fit a tongue-lateralizing or tongue-depressing stent
• Severe trismus with an incisal opening of < 10 mm
• Inability to comply with the study procedures
• Patients younger than 18 years of age
• Patients must not be pregnant

Related Conditions & MeSH terms

• Carcinoma
• Head and Neck Carcinoma
• Maxillary Sinus Carcinoma
• Nasal Cavity Carcinoma
• Oral Cavity Carcinoma
• Parotid Neoplasms
• Tongue Carcinoma

Intervention

Other:
• Best Practice
Receive standard of care
• Medical Device Usage and Evaluation
Wear 3D printed oral stent

Locations

Country	Name	City	State
United States	Cooper Hospital University Medical Center	Camden	New Jersey
United States	M D Anderson Cancer Center	Houston	Texas
United States	Baptist MD Anderson Cancer Center	Jacksonville	Florida
United States	Banner Health/Banner Research	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mucositis toxicity rates	Rate of non-target mucose will be estimated along with the corresponding 95% confidence interval. Cochran-Mantel-Haenszel (CHM) test will be applied to compare mucositis rates between the two treatment arms. Logistic regression will be used to compare occurrence of mucositis between two arms, adjusting for the effects of stratification factors as well as other covariates. T test or Wilcoxon rank sum test will be used to compare three Olerud-Molander Ankle Score between two arms: a mean mucositis score, an extent of mucositis score, and a worst site score.	Through study completion, an average of 1 year
Secondary	Patient reported outcomes	Will be assessed using the MD Anderson Symptom Inventory Head and Neck questionnaire. T test or Wilcoxon rank sum test will be used to compare scores of each item per time point or sums of scores across all items at each time point or sums across three time point per item between the two arms. Multivariate analyses such as linear regression model adjusting for the effects of covariates might be performed to compare patients reported outcomes. Appropriate data transformation will be performed if necessary for assumption of normality.	Through study completion, an average of 1 year
Secondary	Patients narcotics diaries	Will record the worst, the least, the average pain score and pain score at present for each day. Will calculate the average of these 4 scores as a composite daily pain score.	Through study completion, an average of 1 year
Secondary	Imaging difference	The set up error during radiation will be measured in each treatment arm.	Through study completion, an average of 1 year
Secondary	Dosimetric difference	The radiation dose to healthy tissue will be measured in each treatment arm.	Through study completion, an average of 1 year
Secondary	Composite pain scores	An area under curve of pain scores over two weeks (AUC2wks) will be calculated for each patient, and the t test or Wilcoxon rank sum test will be used to compare the AUC2wks of pain scores between the two arms, and between patients with and without occurrence of mucositis in their non-target mucosa. Will also fit linear mixed models including patients as random effects to compare the composite pain scores over two weeks between treatment arms. The linear mixed models will also be fitted to evaluate the association of composite pain scores with occurrence of their non-target mucosa.	Through study completion, an average of 1 year
Secondary	Number of narcotic pills used	An AUC2wks will be calculated for each patient, and the t test or Wilcoxon rank sum test will be used to compare the AUC2wks of pain scores between the two arms, and between patients with and without occurrence of mucositis in their non-target mucosa. Will also fit linear mixed models including patients as random effects to compare the composite pain scores over two weeks between treatment arms.	Through study completion, an average of 1 year

External Links

•   M D Anderson Cancer Center